Eptifibatide induced thrombocytopenia
preprint
OA: closed
Abstract
Glycoprotein (GP) IIb/IIIa are now being widely used in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). With the growing use of these medications, there is an increase in adverse events related to them being reported in the literature, including severe thrombocytopenia.
My notes (saved in your browser only)
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
Source provenance
- europepmc
- last seen: 2026-05-19T01:45:01.086888+00:00